Alvotech (NasdaqGM:ALVO) Valuation Check After FDA Form 483 And Reaffirmed Approval Timelines

Simply Wall St.

05/17

Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2636099741"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636099741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636099741?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-17 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636099741","market":"sg","top_or_hot":-1,"title":"Alvotech (NasdaqGM:ALVO) Valuation Check After FDA Form 483 And Reaffirmed Approval Timelines","media":"Simply Wall St.","content":"<div>\n<p>Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-nasdaqgmalvo-valuation-check-after-fda-form-483-and\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alvotech (NasdaqGM:ALVO) Valuation Check After FDA Form 483 And Reaffirmed Approval Timelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlvotech (NasdaqGM:ALVO) Valuation Check After FDA Form 483 And Reaffirmed Approval Timelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 15:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-nasdaqgmalvo-valuation-check-after-fda-form-483-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-nasdaqgmalvo-valuation-check-after-fda-form-483-and\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-nasdaqgmalvo-valuation-check-after-fda-form-483-and","article_id":"2636099741","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-nasdaqgmalvo-valuation-check-after-fda-form-483-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636099741","pubTimestamp":1779003322,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics License Application resubmissions and approvals.\nSee our latest analysis for Alvotech.\nDespite the reassuring regulatory update and recent earnings and guidance announcements, Alvotech’s share price has been under pressure, with the 30 day share price return down 8.31% and the year to date share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","ALVO":"Alvotech","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"Alvotech(NasdaqGM：ALVO)在FDA 483表格后进行估值检查并重申批准时间表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"ALVO":1.5},"content_text":"Alvotech (NasdaqGM:ALVO) stock is in focus after the FDA completed a routine cGMP inspection of its Reykjavik facility, issuing a Form 483 while the company reaffirmed timelines for key Biologics License Application resubmissions and approvals. See our latest analysis for Alvotech. Despite the reassuring regulatory update and recent earnings and guidance announcements, Alvotech’s share price has been under pressure, with the 30 day share price return down 8.31% and the year to date share price return down 33.80%, while the 1 year total shareholder return has fallen 68.36%. This suggests momentum has been weak even as investors reassess regulatory and earnings risks. If this kind of regulatory news has you rethinking your sector exposure, it could be a good time to look at other healthcare companies applying AI to drug development and manufacturing via the 32 healthcare AI stocks With the stock down sharply over the past year and trading at an apparent discount to analyst targets and some valuation metrics, should you view Alvotech as undervalued today, or is the market already pricing in its future growth? AdvertisementMost Popular Narrative: 76.4% Undervalued With Alvotech’s fair value in the most followed narrative set at $14.00 against a last close of $3.31, the gap between story and share price is wide.  Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.  Read the complete narrative. Curious what earnings path, revenue build up and margin shift need to line up for that fair value to make sense? The narrative leans on ambitious growth, richer profitability and a premium future multiple working together. The full breakdown shows exactly how those moving parts are stitched into a single valuation story. Result: Fair Value of $14.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story only holds if regulatory timelines stay on track and if the heavy reliance on milestone payments does not expose you to sharper than expected earnings swings. Find out about the key risks to this Alvotech narrative. Next Steps With a mixed setup of risks and potential rewards in play, it makes sense to check the figures directly and form your own view using the 3 key rewards and 2 important warning signs. Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that better fit your goals, risk comfort and income needs. Consider widening your view before making your next move.  Target higher quality value opportunities by scanning 51 high quality undervalued stocks that combine attractive prices with solid fundamentals. Strengthen your income focus by reviewing 13 dividend fortresses that aim to deliver robust yields supported by underlying cash flows. Dial down portfolio risk by filtering for 65 resilient stocks with low risk scores that score well on balance sheet strength and earnings stability.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}